5 active not recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) Tibulizumab, Placebo - Systemic Sclerosis (SSc), Scleroderma | Phase 2 | Active not recruiting | Zura Bio Inc | 80 | 2025-02-06 | 2026-07-20 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis rapcabtagene autoleucel, rituximab - Scleroderma, Diffuse | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 96 | 2024-10-29 | 2026-09-02 |
| A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis Placebo, Ianalumab - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 201 | 2024-10-09 | 2026-10-13 |
| Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Tulisokibart, Companion diagnostic ( CDx), Placebo - Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease | Phase 2 | Active not recruiting | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 154 | 2022-03-29 | 2026-09-22 |
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Oral Ifetroban, Oral Placebo - Scleroderma, Diffuse, Scleroderma, Systemic | Phase 2 | Active not recruiting | Cumberland Pharmaceuticals | 34 | 2017-01-01 | 2026-09-02 |
Autoimmune Diseases (2) · Lung Diseases, Interstitial (2) · Scleroderma, Systemic (2) · Skin Diseases (2) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Pathologic Processes (1) · Scleroderma, Limited (1)
Skin and Connective Tissue Diseases (5) · Connective Tissue Diseases (4) · Scleroderma, Systemic (3) · Skin Diseases (3) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Immune System Diseases (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (1) · ianalumab (1) · ifetroban (1)
Novartis Pharmaceuticals (2) · Cumberland Pharmaceuticals (1) · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Zura Bio Inc (1)
United States (5) · Argentina (4) · Hungary (4) · Mexico (4) · Spain (4) · United Kingdom (4) · Belgium (3) · France (3) · Germany (3) · Italy (3) · Poland (3) · Australia (2) · Austria (2) · Brazil (2) · Chile (2)
Evan Brittain, MD (1) · Prometheus Biosciences (1)
2023 (2)